Chemo-enzymatic synthesis of ester-linked taxol-oligosaccharide conjugates as potential prodrugs

Tetrahedron Letters

Volumn 49, Issue 4, 2008, Pages 601-604

  Shimoda, Kei ^a   Hamada, Hatsuyuki ^b   Hamada, Hiroki ^c  

^a OITA UNIVERSITY   (Japan)

^b NATIONAL INSTITUTE OF FITNESS AND SPORTS IN KANOYA   (Japan)

^c OKAYAMA UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 GLYCOPACLITAXEL 2' O ALPHA GLUCOOLIGOSACCHARIDE; 7 GLYCOPACLITAXEL 2' O ALPHA GLUCOPENTAOSIDE; 7 GLYCOPACLITAXEL 2' O ALPHA GLUCOPYRANOSIDE; 7 GLYCOPACLITAXEL 2' O ALPHA GLUCOTETRAOSIDE; ALPHA GLUCOSIDASE; CYCLOMALTODEXTRIN GLUCANOTRANSFERASE; OLIGOSACCHARIDE; PACLITAXEL; PRODRUG; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CYTOTOXICITY; DRUG ACTIVITY; DRUG SOLUBILITY; DRUG SYNTHESIS; ENZYME GLYCOSYLATION; HUMAN; HUMAN CELL;

EID: 37549011827     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2007.11.156     Document Type: Article

References (17)

1. Nicolaou K.C., Dai W.-M., and Guy R.K. Angew. Chem., Int. Ed. Engl. 33 (1994) 15
2. Greenwald R.B., Gilbert C.W., Pendri A., Conover C.D., Xia J., and Martinez A. J. Med. Chem. 39 (1996) 424
3. Hayashi Y., Skwarczynski M., Hamada Y., Sohma Y., Kimura T., and Kiso Y. J. Med. Chem. 46 (2003) 3782
4. Bradley M.O., Webb N.L., Anthony F.H., Devanesan P., Witman P.A., Hemamalini S., Chander M.C., Baker S.D., He L.F., Horwitz S.B., and Swindell C.S. Clin. Cancer Res. 7 (2001) 3229
5. Battaglia A., Guerrini A., Baldelli E., Fontana G., Varchi G., Samori C., and Bombardelli E. Tetrahedron Lett. 47 (2006) 2667
6. Khmelnitsky Y.L., Budde C., Arnold J.M., Usyatinsky A., Clark D.S., and Dordick J.S. J. Am. Chem. Soc. 119 (1997) 11554
7. Luo Y., and Prestwich G.D. Bioconjugate Chem. 10 (1999) 755
8. Luo Y., Ziebell M.R., and Prestwich G.D. Biomacromolecules 1 (2000) 208
9. Skwarczynski M., Hayashi Y., and Kiso Y. J. Med. Chem. 49 (2006) 7253
10. Gonsho A., Irie K., Susaki H., Iwasawa H., Okuno S., and Sugawara T. Biol. Pharm. Bull. 17 (1994) 275
11. Hashida M., Hirabayashi H., Nishikawa M., and Takakura Y. J. Control. Release 46 (1997) 129
12. Kaminaga Y., Nagatsu A., Akiyama T., Sugimoto N., Yamazaki T., Maitani T., and Mizukami H. FEBS Lett. 555 (2003) 311
13. 3 in 4Ac), 26.7 (C-17), 34.1 (C-6), 36.3 (C-14), 44.6 (C-3, C-15), 57.1 (C-3′), 57.7 (C-8)
14. 2O (2:3, v/v); detection: UV (228 nm); flow rate: 1.0 mL/min].
15. 5 cells/mL), suspended in 96-well tissue culture plates (100 μL/well), preincubated at 37 °C for 4 h, and then treated for 24 h with paclitaxel or 4-8 at various concentrations to obtain a dose-response curve for each compound. After incubation, 20 μL MTT solution (2.5 mg/mL) was added to each well and the plates were further incubated for 4 h. Absorbance at 570 nm was measured with a microplate reader model 450 (BIO-RAD). Dose-response curves were plotted on a semi-log scale as percentage of the cell numbers in control cultures not exposed to test compounds.
16. Mosmann T. J. Immunol. Meth. 65 (1983) 55
17. 2 fractions were combined, concentrated, and analyzed by HPLC. The yield of the product, paclitaxel, was calculated on the basis of the peak area from HPLC using a calibration curve provided by HPLC analyses of authentic paclitaxel. Yields of paclitaxel from compounds 4-8 were 3%, 1%, trace, 0%, and 0%, respectively.